Iceland· IS-EU/1/22/1675/001

Tecvayli

A teclistamab product containing teclistamabum inn, registered in Iceland by Janssen-Cilag International NV*. The same ATC class is registered in 14 of our 19 countries.

ATC L01FX24

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedTecvayliATCL01FX24REGISTER NO.IS-EU/1/22/1675/001PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Teclistamab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FX24 (teclistamab), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 9 of them publish a price we can compare per daily dose

Teclistamab · ATC L01FX24

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Teclistamabum INN
Manufacturer
Janssen-Cilag International NV*
Country
Iceland (IS)
ATC code
L01FX24
ATC class
Teclistamab
Defined daily dose
15 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 1

1 priced
  • ean
    179618
    3 ml x1 hgl
    ISK 183336

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Teclistamab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All teclistamab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Tecvayli
  • Norway · Tecvayli

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f7b6bb55-8fd0-4f4c-8cf7-ccd0f72f6443
GET /v1/drugs/f7b6bb55-8fd0-4f4c-8cf7-ccd0f72f6443?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn",
  "source": "lyfjastofnun",
  "atc_raw": "L01FX24",
  "marketed": true,
  "strength": "10 mg/ml",
  "ma_number": "EU/1/22/1675/001",
  "substance": "Teclistamabum INN",
  "other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
  "ma_issued_serial": "44796"
}

See everything about teclistamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.